Form 4: Theravance Biopharma CFO Aziz Sawaf Reports Share Disposal for Tax Obligations
SEC Form 4 Filing
Aziz Sawaf, SVP & CFO of Theravance Biopharma, disposed of 9,348 ordinary shares to cover tax obligations arising from vesting restricted stock units.
Summary
- On May 20, 2025, Aziz Sawaf, the SVP & CFO of Theravance Biopharma, disposed of 9,348 ordinary shares.
- The shares were withheld to satisfy tax obligations related to the vesting of previously granted restricted stock units.
- The transaction was conducted with the issuer and did not involve an open market transaction.
- Following the transaction, Sawaf beneficially owns 364,790 ordinary shares.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing reflects a routine transaction for tax purposes.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Related Party Transactions
- The share withholding transaction was with the issuer.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a standard procedure for covering tax obligations.
Key Dates
| Date | Description |
|---|---|
| 05/20/2025 | Date of share disposal transaction |
| 05/22/2025 | Date of signature by Attorney-in-Fact |
Keywords
Form 4, Theravance Biopharma, TBPH, Aziz Sawaf, CFO, Share Disposal, Tax Obligations, Restricted Stock Units, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.